<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Palbociclib isethionate - PD 0332991 isethionate

產(chǎn)品貨號

Axon 2052 CAS [827022-33-3] MF C24H29N7O2.C2H6O4SMW 573.66 Purity: 99% Soluble in water and DMSO Description An orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6; a potential agent for the treatment of breast cancer. Another salt form, PD 0332991 hydrochloride (Axon 1505) is also available. References Certificates Categories Extra info Malini Guha. Blockbuster dreams for Pfizer's CDK inhibitor. Nature Biotech. 2013, 31, 187.? ? RL Sutherland and EA Musgrove. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009, 11(6), 112-113. ? RS Finn et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11(5), R77.? ? DW Fry et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438. Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology p53-Tumor Suppression EC 2.7.11.22 CDK Pfizer Licensed Products Orally active cyclin-dependent kinase (CDK4/6) inhibitor Chemical name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one 2-hydroxyethanesulfonate Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [571190-30-2] Order Size Unit Price Stock 10 mg €125.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Palbociclib isethionate - PD 0332991 isethionate

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 2052

CAS [827022-33-3]

MF C24H29N7O2.C2H6O4S
MW 573.66

Purity: 99%
Soluble in water and DMSO

Palbociclib isethionate

Description

An orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6; a potential agent for the treatment of breast cancer.

Another salt form, PD 0332991 hydrochloride (Axon 1505) is also available.

Malini Guha. Blockbuster dreams for Pfizer's CDK inhibitor. Nature Biotech. 2013, 31, 187.?

RL Sutherland and EA Musgrove. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009, 11(6), 112-113.

RS Finn et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11(5), R77.?

DW Fry et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438.

Certificate of Analysis
Material Safety Data Sheet

Cell Cycle Regulation Cell Signaling & Oncology p53-Tumor Suppression EC 2.7.11.22 CDK Pfizer Licensed Products

Orally active cyclin-dependent kinase (CDK4/6) inhibitor

Chemical name

6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one 2-hydroxyethanesulfonate

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[571190-30-2]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>